# Single Ascending Oral Dose Study of F901318

> **NCT02394483** · PHASE1 · COMPLETED · sponsor: **F2G Ltd** · enrollment: 46 (actual)

## Conditions studied

- Invasive Aspergillosis

## Interventions

- **DRUG:** F901318 safety
- **DRUG:** F901318 tolerability
- **DRUG:** F901318 pharmacokinetics
- **OTHER:** Placebo safety
- **OTHER:** Placebo tolerability
- **OTHER:** Placebo pharmacokinetics

## Key facts

- **NCT ID:** NCT02394483
- **Lead sponsor:** F2G Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2016-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02394483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02394483, "Single Ascending Oral Dose Study of F901318". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02394483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*